Trial Profile
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacodynamics; Pharmacokinetics
- Acronyms PROMISE
- 15 May 2023 Results from P1084s substudy (n=400 ) assessing Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment , published in the JAIDS
- 16 Feb 2022 Results assessing outcomes in a subset of mother-infant (MI) pairs randomized to either maternal TDF-based ART [TDF/ FTC+LPV/r] (mART) or infant nevirapine prophylaxis [no maternal ART] (iNVP) during breastfeeding as part of the IMPAACT PROMISE study, presented at the 29th Conference on Retroviruses and Opportunistic Infections.
- 10 Mar 2021 Results estimating the association between hair TFV levels and viremia using subset of women randomized in this trial presented at the 28th Conference on Retroviruses and Opportunistic Infections